View ValuationSartorius 将来の成長Future 基準チェック /46Sartorius利益と収益がそれぞれ年間20.7%と8.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に17.4% 16.2%なると予測されています。主要情報20.7%収益成長率16.16%EPS成長率Life Sciences 収益成長20.2%収益成長率8.8%将来の株主資本利益率17.41%アナリストカバレッジGood最終更新日22 May 2026今後の成長に関する最新情報お知らせ • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.お知らせ • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.お知らせ • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.すべての更新を表示Recent updatesBuy Or Sell Opportunity • May 11Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.2% to €215. The fair value is estimated to be €274, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.Reported Earnings • Apr 24First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €899.1m (up 1.8% from 1Q 2025). Net income: €56.2m (up 16% from 1Q 2025). Profit margin: 6.3% (up from 5.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.Upcoming Dividend • Mar 20Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 27 March 2026. Payment date: 31 March 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Italian dividend payers (5.0%). Lower than average of industry peers (0.9%).Buy Or Sell Opportunity • Mar 02Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.5% to €234. The fair value is estimated to be €294, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.3% over the last 3 years. Earnings per share has declined by 71%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (91% net debt to equity). Share price has been volatile over the past 3 months (5.2% average weekly change).New Risk • Feb 17New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. This is currently the only risk that has been identified for the company.Reported Earnings • Feb 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.54b (up 4.7% from FY 2024). Net income: €154.9m (up 84% from FY 2024). Profit margin: 4.4% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.お知らせ • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.Buy Or Sell Opportunity • Feb 09Now 21% undervaluedOver the last 90 days, the stock has risen 1.2% to €235. The fair value is estimated to be €298, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.Declared Dividend • Feb 09Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%.お知らせ • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.お知らせ • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.お知らせ • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026お知らせ • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.Buy Or Sell Opportunity • Jan 14Now 21% undervaluedOver the last 90 days, the stock has risen 11% to €254. The fair value is estimated to be €322, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.お知らせ • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026Reported Earnings • Oct 17Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €843.2m (up 6.3% from 3Q 2024). Net income: €43.8m (up 209% from 3Q 2024). Profit margin: 5.2% (up from 1.8% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe.お知らせ • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.Reported Earnings • Jul 24Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €884.3m (up 2.7% from 2Q 2024). Net income: €32.5m (up 35% from 2Q 2024). Profit margin: 3.7% (up from 2.8% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.New Risk • Jul 04New major risk - Revenue and earnings growthEarnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.0% per year over the past 5 years. Minor Risks High level of debt (93% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin).お知らせ • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Buy Or Sell Opportunity • May 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to €227. The fair value is estimated to be €285, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.お知らせ • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.Reported Earnings • Apr 16First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: €0.70. Revenue: €883.0m (up 7.7% from 1Q 2024). Net income: €48.5m (up 32% from 1Q 2024). Profit margin: 5.5% (up from 4.5% in 1Q 2024). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.業績と収益の成長予測BIT:1SRT3 - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20284,5073857211,1261912/31/20274,1063305841,0152212/31/20263,752258443839223/31/20263,554163443887N/A12/31/20253,538155395837N/A9/30/20253,517134479874N/A6/30/20253,468104575919N/A3/31/20253,444967121,070N/A12/31/20243,38184566976N/A9/30/20243,32478479924N/A6/30/20243,34178350838N/A3/31/20243,312149144697N/A12/31/20233,396206294854N/A9/30/20233,608358215821N/A6/30/20233,850495204807N/A3/31/20234,053566182744N/A12/31/20224,175678212734N/A9/30/20224,035534175690N/A6/30/20223,880489243723N/A3/31/20223,683434414837N/A12/31/20213,449319466873N/A9/30/20213,183372422770N/A6/30/20212,908332439737N/A3/31/20212,617254350627N/A12/31/20202,336210271512N/A9/30/20202,151181312503N/A6/30/20201,989154227427N/A3/31/20201,901165171385N/A12/31/20191,827157N/A377N/A9/30/20191,768171N/A337N/A6/30/20191,702166N/A318N/A3/31/20191,637153N/A312N/A12/31/20181,566141N/A245N/A9/30/20181,518138N/A245N/A6/30/20181,460126N/A244N/A3/31/20181,426115N/A223N/A12/31/20171,405115N/A207N/A9/30/20171,37691N/A185N/A6/30/20171,37796N/A182N/A3/31/20171,341105N/A173N/A12/31/20161,300103N/A170N/A9/30/20161,25099N/A145N/A6/30/20161,205101N/A112N/A3/31/20161,15996N/A132N/A12/31/20151,11585N/A125N/A9/30/20151,07676N/A160N/A6/30/20151,00361N/A153N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1SRT3の予測収益成長率 (年間20.7% ) は 貯蓄率 ( 3.3% ) を上回っています。収益対市場: 1SRT3の収益 ( 20.7% ) はItalian市場 ( 11.1% ) よりも速いペースで成長すると予測されています。高成長収益: 1SRT3の収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: 1SRT3の収益 ( 8.8% ) Italian市場 ( 5.8% ) よりも速いペースで成長すると予測されています。高い収益成長: 1SRT3の収益 ( 8.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1SRT3の 自己資本利益率 は、3年後には低くなると予測されています ( 17.4 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:50終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sartorius Aktiengesellschaft 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。38 アナリスト機関Charles PitmanBarclaysCharles PitmanBarclaysHarry GillisBerenberg35 その他のアナリストを表示
お知らせ • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.
お知らせ • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.
お知らせ • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.
Buy Or Sell Opportunity • May 11Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.2% to €215. The fair value is estimated to be €274, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.
Reported Earnings • Apr 24First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €899.1m (up 1.8% from 1Q 2025). Net income: €56.2m (up 16% from 1Q 2025). Profit margin: 6.3% (up from 5.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.
Upcoming Dividend • Mar 20Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 27 March 2026. Payment date: 31 March 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Italian dividend payers (5.0%). Lower than average of industry peers (0.9%).
Buy Or Sell Opportunity • Mar 02Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.5% to €234. The fair value is estimated to be €294, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.3% over the last 3 years. Earnings per share has declined by 71%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.
New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (91% net debt to equity). Share price has been volatile over the past 3 months (5.2% average weekly change).
New Risk • Feb 17New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. This is currently the only risk that has been identified for the company.
Reported Earnings • Feb 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.54b (up 4.7% from FY 2024). Net income: €154.9m (up 84% from FY 2024). Profit margin: 4.4% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.
お知らせ • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.
Buy Or Sell Opportunity • Feb 09Now 21% undervaluedOver the last 90 days, the stock has risen 1.2% to €235. The fair value is estimated to be €298, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.
Declared Dividend • Feb 09Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%.
お知らせ • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.
お知らせ • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.
お知らせ • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026
お知らせ • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.
Buy Or Sell Opportunity • Jan 14Now 21% undervaluedOver the last 90 days, the stock has risen 11% to €254. The fair value is estimated to be €322, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.
お知らせ • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026
Reported Earnings • Oct 17Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €843.2m (up 6.3% from 3Q 2024). Net income: €43.8m (up 209% from 3Q 2024). Profit margin: 5.2% (up from 1.8% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe.
お知らせ • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.
Reported Earnings • Jul 24Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €884.3m (up 2.7% from 2Q 2024). Net income: €32.5m (up 35% from 2Q 2024). Profit margin: 3.7% (up from 2.8% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
New Risk • Jul 04New major risk - Revenue and earnings growthEarnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.0% per year over the past 5 years. Minor Risks High level of debt (93% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin).
お知らせ • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)
Buy Or Sell Opportunity • May 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to €227. The fair value is estimated to be €285, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.
お知らせ • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.
Reported Earnings • Apr 16First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: €0.70. Revenue: €883.0m (up 7.7% from 1Q 2024). Net income: €48.5m (up 32% from 1Q 2024). Profit margin: 5.5% (up from 4.5% in 1Q 2024). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.